𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Factors potentiating the risk of mirtazapine-associated restless legs syndrome

✍ Scribed by Sung-Wan Kim; Il-Seon Shin; Jae-Min Kim; Kee-Hyung Park; Tak Youn; Jin-Sang Yoon

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
75 KB
Volume
23
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective

Mirtazapine is known to often provoke restless legs syndrome (RLS). In this retrospective chart review study, we evaluated the socio‐demographic and clinical factors related to mirtazapine‐associated RLS.

Methods

Computerized medical records of 181 patients treated with mirtazapine from May 2004 to October 2007 were reviewed. RLS was identified using the diagnostic criteria of the International RLS Study Group. Socio‐demographic and clinical characteristics were gathered, including comorbid physical illness and concomitant medications.

Results

Mirtazapine‐associated RLS was observed in 14 patients (8%), and most cases had developed within a few days after starting mirtazapine. Concomitant medication with tramadol, non‐opioid analgesics, antihistamine, and dopamine‐blocking agents was more frequently prescribed in subjects developing mirtazapine‐associated RLS. In logistic regression analysis, concomitant medication with tramadol (odds ratio: 8.61, 95% confidence interval: 1.71–43.49) and dopamine‐blocking agents (odds ratio: 4.67, 95% confidence interval: 1.31–16.70) enhanced the risk of mirtazapine‐associated RLS.

Conclusion

The combined use of mirtazapine with tramadol or dopamine‐blocking agents could potentiate the risk of RLS. Clinician should watch carefully for the development of RLS when mirtazapine is administered to patients who are taking tramadol or dopamine‐blocking agents. Copyright © 2008 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Family-based and population-based associ
Family-based and population-based association studies validate PTPRD as a risk factor for restless legs syndrome
✍ Qinbo Yang; Lin Li; Rong Yang; Gong-Qing Shen; Qiuyun Chen; Nancy Foldvary-Schae 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 1 views

## Abstract ## Objective: We previously mapped a genetic locus for restless legs syndrome (RLS) to chromosome 9p22‐24 (__RLS3__) and a later genome‐wide association study (GWAS) implicated the __PTPRD__ gene at the __RLS3 l__ocus as a susceptibility gene for RLS. However, from the standpoint of ge

Deep brain stimulation of the GPi treats
Deep brain stimulation of the GPi treats restless legs syndrome associated with dystonia
✍ Michael S. Okun; Hubert H. Fernandez; Kelly D. Foote 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB 👁 1 views

## Abstract We report on the case of a woman with generalized dystonia and restless legs syndrome whose restless legs resolved after bilateral internal globus pallidus deep brain stimulation, and recurred unilaterally after an infection required removal of one of the devices. © 2004 Movement Disord

Factors contributing to the development
Factors contributing to the development of restless legs syndrome in patients with Parkinson disease
✍ Ji E. Lee; Hae-Won Shin; Kyung S. Kim; Young H. Sohn 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB 👁 1 views

## Abstract Although restless legs syndrome (RLS) commonly accompanies Parkinson disease (PD), the mechanism of RLS development in PD is still unclear. We investigated the prevalence of RLS in Korean patients with PD, and the possible contributing factors to the development of RLS in those patients

Family-based association study of the re
Family-based association study of the restless legs syndrome loci 2 and 3 in a European population
✍ David Kemlink; Olli Polo; Pasquale Montagna; Federica Provini; Karin Stiasny-Kol 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Abstract Three loci for the restless legs syndrome (RLS) on chromosomes 12q, 14q, and 9p (RLS1, RLS2, and RLS3) have been mapped, but no gene has been identified as yet. RLS1 has been confirmed in families from three different populations. We conducted a family‐based association study of 159 Eur

Immunogenetic risk and protective factor
Immunogenetic risk and protective factors for the development of L-tryptophan-associated eosinophilia-myalgia syndrome and associated symptoms
✍ Okada, Satoshi ;Kamb, Mary L. ;Pandey, Janardan P. ;Philen, Rossanne M. ;Love, L 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 2 views

## Abstract ## Objective To assess L‐tryptophan (LT) dose, age, sex, and immunogenetic markers as possible risk or protective factors for the development of LT‐associated eosinophilia–myalgia syndrome (EMS) and related clinical findings. ## Methods HLA–DRB1 and DQA1 allele typing and Gm/Km pheno